MANNKIND CORP Payments of Stock Issuance Costs
MANNKIND CORP (MNKD) reported Payments of Stock Issuance Costs of $3.12 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2024-02-27
- MANNKIND CORP payments of stock issuance costs for the quarter ending 2018-09-30 was $8.00K.
- MANNKIND CORP payments of stock issuance costs for the quarter ending 2018-06-30 was $0.00.
- MANNKIND CORP payments of stock issuance costs for the quarter ending 2018-03-31 was $25.00K.
- MANNKIND CORP payments of stock issuance costs for the quarter ending 2015-12-31 was $277.00K.
- MANNKIND CORP payments of stock issuance costs for fiscal 2021 was $3.12M.
- MANNKIND CORP payments of stock issuance costs for fiscal 2017 was $17.00K.
- MANNKIND CORP payments of stock issuance costs for fiscal 2015 was $548.00K.
- MANNKIND CORP payments of stock issuance costs for fiscal 2013 was $1.10M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2021-12-31 | $3.12M 10-K · filed 2024-02-27 | |||
| 2018-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $8.00K derived: sum of 2 quarters · filed 2018-11-01 | $33.00K 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $25.00K 10-Q · filed 2018-08-02 | ||
| 2018-03-31 | $25.00K 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | $17.00K 10-K · filed 2018-02-27 | |||
| 2015-12-31 | $277.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $548.00K 10-K · filed 2018-02-27 | ||
| 2015-09-30 | $271.00K 10-Q · filed 2016-11-09 | |||
| 2013-12-31 | $1.10M 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |